Clinical trials: Pregnancy Complications
Renal Insufficiency
Evaluation of the Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Without Exposure to Gadolinium Based Contrast Agents (GBCA)
The objective of this long term study is to prospectively evaluate the incidence of NSF in patients with severe CKD or kidney failure including patients undergoing dialysis (stages 4 and 5 i.e., with an eGFR below 30)who have not…
- Trial name
- NCT00773409
- Where
- United States
- Volunteers
- 405 people
- Sponsor
- Bracco Diagnostics, Inc
Chronic Kidney Disease
Efficacy and Safety of the Ultrasound Stimulation Device NEFRONIX in Patients With Chronic Kidney Disease
This study is a prospective, multicenter, single-arm, open-label, non-randomized exploratory clinical trial designed to evaluate the safety and potential efficacy of an ultrasound stimulation device (NEFRONIX G-01) in patients…
- Trial name
- NCT07339098
- Testing
- Ultrasound Stimulation (NEFRONIX G-01)
- Volunteers
- 20 people
- Sponsor
- Anasonic
Neoplasms
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
The purpose of this study is to evaluate if the combination of GSK3359609 and tremelimumab is safe and tolerable (Part 1) and provides significant survival benefit to subjects with relapsed/refractory (R/R) Head and Neck Squamous…
- Trial name
- NCT03693612
- Testing
- feladilimab, Tremelimumab, Docetaxel
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 26 people
- Sponsor
- GlaxoSmithKline
Urinary Incontinence , Stress
Monocentric Pilot Study for the Application of an Endourethral Device for the Treatment of Stress Urinary Incontinence
Stress urinary incontinence is defined as the involuntary loss of urine during exertion or physical activity (i.e., sports) or during sneezing or coughing.
- Trial name
- CIP-003 (NCT07327528)
- Testing
- UroRelief, a sterile, single-use, endourethral medical device suitable for both men and women, which is positioned at the bladder neck for the treatment of stress incontinence.
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Relief srl
Birth Defects, Pregnancy Complications
UCB Antiepileptic Drugs (AED) Pregnancy Registry (Formerly the Keppra® Pregnancy Registry)
This is a prospective, observational, exposure-registration and follow-up study of women and their offspring exposed to Keppra® (levetiracetam) and Keppra XR® at the time of conception (i.e., any time from the first day of the…
- Conditions
- Birth Defects, Pregnancy Complications, Epilepsy, Seizures
- Trial name
- NCT00345475
- Where
- United States
- Volunteers
- 516 people
- Sponsor
- UCB Pharma
Female Infertility, Oocyte Competence
Adipose Stem Cell Mitochondria Supplementation to Oocytes (ASCENT)
The purpose of this study is to investigate the potential of autologous adipose stem cell (ASC) mitochondrial transfer (ASCENT) to oocytes along with intracytoplasmic sperm injection (ICSI)as a means of enhancing embryo…
- Conditions
- Female Infertility, Oocyte Competence, Mitochondria, Recurent Implantation Failures
- Trial name
- NCT07066267
- Testing
- Experimental
- Where
- Sri Lanka
- Volunteers
- 20 people
- Sponsor
- Sunkaky Medical Cooperation
Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with…
- Conditions
- Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT05281471
- Testing
- olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin
- Where
- 33 sites in United States
- Volunteers
- 186 people
- Sponsor
- Genelux Corporation
Urinary Bladder Cancer, Melanoma
MAGE-A4ᶜ¹º³²T for Multi-Tumor
This study will investigate the safety and tolerability of MAGE-A4ᶜ¹º³²T cell therapy in subjects who have the appropriate HLA-A2 tissue marker and whose urinary bladder, melanoma, head and neck, ovarian, non-small cell lung…
- Conditions
- Urinary Bladder Cancer, Melanoma, Head and Neck Cancer, Ovarian Cancer
- Trial name
- NCT03132922
- Testing
- Autologous genetically modified MAGE-A4ᶜ¹º³²T cells, Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
- Where
- 11 sites in United States, Canada
- Volunteers
- 71 people
- Sponsor
- USWM CT, LLC
Bladder Cancer, Non Muscle Invasive
Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer
The purpose of this study is to determine the safety and tolerability of intravesical BH011 in patients with high-risk non-muscle invasive bladder cancer（NMIBC） after Bacillus Calmette-Guerin（BCG） failure and to assess the…
- Trial name
- NCT06732531
- Testing
- BH011
- Where
- 6 sites in China
- Volunteers
- 48 people
- Sponsor
- Zhuhai Beihai Biotech Co., Ltd
IgA Nephropathy, CKD Associated With Type 1 Diabetes
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
This multi-center, open-label Phase 2 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with the following rare chronic kidney diseases (CKD): CKD associated with type 1 diabetes…
- Conditions
- IgA Nephropathy, CKD Associated With Type 1 Diabetes, Focal Segmental Glomerulosclerosis, Autosomal Dominant Polycystic Kidney
- Trial name
- PHOENIX (NCT03366337)
- Testing
- Bardoxolone methyl capsules
- Where
- 30 sites in United States
- Volunteers
- 103 people
- Sponsor
- Biogen
Thrombotic Microangiopathies
Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies
The purpose of this study is to assess the safety, efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of OMS721 in patients with thrombotic microangiopathies (TMA).
- Trial name
- NCT02222545
- Testing
- OMS721
- Where
- 24 sites in United States, Belgium and 10 more
- Volunteers
- 58 people
- Sponsor
- Omeros Corporation
End Stage Renal Disease, AV Fistula
Percutaneous Less Invasive AV Fistula for Vascular Access in ESRD
A prospective single-arm well-controlled study to evaluate the safety and effectiveness of a less invasive means of establishing vascular access to facilitate dialysis in patients with end stage renal disease.
- Conditions
- End Stage Renal Disease, AV Fistula, Fistula, End Stage Kidney Disease
- Trial name
- NCT02363972
- Testing
- Ellipsys Vascular Access Catheter
- Where
- 5 sites in United States
- Volunteers
- 103 people
- Sponsor
- Medtronic Endovascular
Urinary Tract Infections
Cefepime/AAI101 Phase 2 Study in Hospitalized Adults With cUTI
Phase 2, randomised, double-blind, 2-cohort study in hospitalised adults with complicated urinary tract infection (cUTI), including acute pyelonephritis. All study cohorts were randomised in a 2:1 ratio.
- Trial name
- NCT03680612
- Testing
- Cefepime 1G - 2G / AAI101 0.5G - 0.75G, cefepime 1 g or cefepime 2 g
- Where
- 5 sites in Czechia, Hungary and 3 more
- Volunteers
- 45 people
- Sponsor
- Allecra
Urinary Calculi, Benign Prostatic Hyperplasia
Flexiva Pulse Registry
To obtain post-market safety and efficacy data for FlexivaTM Pulse High Power Single-Use Laser Fibers during lithotripsy and soft tissue procedure of holmium laser enucleation of the prostate (HoLEP).
- Trial name
- NCT05027971
- Testing
- Flexiva Pulse High Power Single-Use Laser Fibers
- Where
- 4 sites in United States
- Volunteers
- 201 people
- Sponsor
- Boston Scientific Corporation
Infections, Herpesviridae
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Eligible subjects will be randomized to receive VALTREX® tablet 1g or placebo once daily for 60 days in a two-way crossover study with a washout period of 7 days between treatment periods.
- Trial name
- NCT00116844
- Testing
- Valaciclovir
- Where
- 17 sites in United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
IgA Nephropathy, Berger Disease
Atacicept in Subjects With IgA Nephropathy
A Phase 3 Study with Atacicept in Subjects With IgA Nephropathy (ORIGIN 3)
- Trial name
- ORIGIN 3 (NCT04716231)
- Testing
- Atacicept
- Where
- United States
- Volunteers
- 428 people
- Sponsor
- Vera Therapeutics, Inc.
Menopausal and Perimenopausal Disorder, Unspecified, Atrophic Vaginitis
Preliminary Study of a Vaginal Lubrication Ring to Treat the Symptoms of Vaginal Dryness
This is a pilot study, assessing the ability and safety of the use of VR101 intravaginal ring to relieve the symptoms of vaginal dryness, in peri and post-menopausal women. VR1010 is designed to release glycerol.
- Trial name
- NCT02029053
- Testing
- Vaginal Lubrication Ring for Vaginal Dryness
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- J3 Bioscience, Inc.
Chronic Kidney Disease
Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia
This is a phase 2, international, multicenter, randomized, double blind, placebo-controlled trial to evaluate the efficacy and safety of ABP-671 in subjects with CKD and hyperuricaemia, to preliminarily evaluate the efficacy of…
- Trial name
- NCT07323095
- Testing
- ABP-671 plus febuxostat Group 1, ABP-671 plus febuxostat Group 2, ABP-671 Group
- Where
- 10 sites in Australia, China
- Volunteers
- 80 people
- Sponsor
- Atom Therapeutics Co., Ltd
Healthy Subjects, Pharmacokinetics of ASP8232
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease
This study consists of two parts. Part 1 evaluates the effect of renal impairment on the PK and PD of a single dose of ASP8232. In addition, the safety and tolerability will be assessed.
- Conditions
- Healthy Subjects, Pharmacokinetics of ASP8232, Pharmacodynamics of ASP8232, Chronic Kidney Disease (CKD)
- Trial name
- NCT02218099
- Testing
- ASP8232
- Where
- 3 sites in Bulgaria, Moldova and 1 more
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
The purpose of this study was to determine the safety and efficacy of ACH-0144471 (also known as danicopan and ALXN2040) in currently untreated participants with PNH.
- Trial name
- NCT03053102
- Testing
- Danicopan
- Where
- 5 sites in Italy, New Zealand and 2 more
- Volunteers
- 10 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.